Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial

Evaluation of pharmacokinetic/pharmacodynamic (PK/PD) properties played an important role in the early clinical development of pembrolizumab. Because analysis of data from a traditional 3 + 3 dose‐escalation design revealed several critical uncertainties, a model‐based approach was implemented to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Elassaiss‐Schaap, J, Rossenu, S, Lindauer, A, Kang, SP, de Greef, R, Sachs, JR, de Alwis, DP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270295/
https://www.ncbi.nlm.nih.gov/pubmed/27863143
http://dx.doi.org/10.1002/psp4.12132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270295/
https://www.ncbi.nlm.nih.gov/pubmed/27863143
http://dx.doi.org/10.1002/psp4.12132

Ejemplares similares